Results 11 to 20 of about 32,113 (291)

Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator

Molecules, 2021
Deferoxamine B is an outstanding molecule which has been widely studied in the past decade for its ability to bind iron and many other metal ions.
Denise Bellotti, Maurizio Remelli
doaj   +2 more sources

Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis

Neural Regeneration Research, 2019
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair.
Xue Yao, Yan Zhang, Jian Hao, Hui-Quan Duan, Chen-Xi Zhao, Chao Sun, Bo Li, Bao-You Fan, Xu Wang, Wen-Xiang Li, Xuan-Hao Fu, Yong Hu, Chang Liu, Xiao-Hong Kong, Shi-Qing Feng   +14 more
doaj   +2 more sources

Deferoxamine Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis and Activating the Nrf2 Pathway

Frontiers in Pharmacology, 2022
Objective: Osteoarthritis (OA) is a common disease with a complex pathology including mechanical load, inflammation, and metabolic factors. Chondrocyte ferroptosis contributes to OA progression.
Zhou Guo, Jiamin Lin, Kai Sun, Jiayou Guo, Xudong Yao, Genchun Wang, Liangcai Hou, Jingting Xu, Jiachao Guo, Fengjing Guo   +9 more
doaj   +2 more sources

Iron Neurotoxicity and Protection by Deferoxamine in Intracerebral Hemorrhage

Frontiers in Molecular Neuroscience, 2022
Intracerebral hemorrhage (ICH) is a subtype of stroke that is characterized by high morbidity and mortality, for which clinical outcome remains poor. An extensive literature indicates that the release of ferrous iron from ruptured erythrocytes in the ...
Zhe Li, Zhe Li, Zhe Li, Yang Liu, Yang Liu, Yang Liu, Ruixue Wei, Ruixue Wei, Ruixue Wei, Suliman Khan, Suliman Khan, Suliman Khan, Ruiyi Zhang, Ruiyi Zhang, Ruiyi Zhang, Yan Zhang, Yan Zhang, Yan Zhang, Voon Wee Yong, Mengzhou Xue, Mengzhou Xue, Mengzhou Xue   +21 more
doaj   +2 more sources

Deferoxamine-Based Materials and Sensors for Fe(III) Detection

Chemosensors, 2022
Deferoxamine (DFO) is a siderophore widely studied for its ability to bind iron(III) strongly. Thanks to its versatility, it is suitable for several clinical and analytical applications, from the recognized iron(III) chelation therapy to the most recent ...
Giancarla Alberti, Camilla Zanoni, Lisa Rita Magnaghi, Raffaela Biesuz   +3 more
doaj   +2 more sources

Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis

Molecules
Deferoxamine, an iron chelator used to treat diseases caused by excess iron, has had a Food and Drug Administration-approved status for many years. A large number of studies have confirmed that deferoxamine can reduce inflammatory response and promote ...
Haijun Shen, Yane Ma, Yi Qiao, Chun Zhang, Jialing Chen, Ran Zhang   +5 more
doaj   +2 more sources

Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats

Neural Regeneration Research, 2017
Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism for this action remains unknown.
Jian Hao, Bo Li, Hui-quan Duan, Chen-xi Zhao, Yan Zhang, Chao Sun, Bin Pan, Chang Liu, Xiao-hong Kong, Xue Yao, Shi-qing Feng   +10 more
doaj   +2 more sources

Cinnamaldehyde and its combination with deferoxamine ameliorate inflammation, ferroptosis and hematoma expansion after intracerebral hemorrhage in mice

Journal of Neuroinflammation
Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available.
Yulin Liu, Guoqiang Yang, Mengnan Liu, Yuwei Zhang, Houping Xu, Maryam Mazhar   +5 more
doaj   +2 more sources

Receptor-Dependent and -Independent Effects of Hemin on Platelet Plasma Membrane Disintegration. [PDF]

FASEB J
Microhemorrhages lead to the release of erythrocytes, which are then degraded and lysed. These hemolyses result in the liberation of free iron‐containing hemin. Hemin induces platelet activation and ferroptosis. Inhibition of GPVI/CLEC‐2 receptor‐mediated ITAM‐signaling inhibits hemin‐induced platelet activation (low hemin concentrations). Deferoxamine,
Laspa Z, Rohlfing AK, Hochuli R, Sowa PW, Castor T, Gawaz MP.   +5 more
europepmc   +2 more sources

Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial

Stroke, 2022
Background: There are limited data on the trajectory of recovery and long-term functional outcomes after intracerebral hemorrhage (ICH). Most ICH trials have conventionally assessed outcomes at 3 months following the footsteps of ischemic stroke.
L. Foster, L. Robinson, S. Yeatts, R. Conwit, A. Shehadah, V. Lioutas, M. Selim   +6 more
semanticscholar   +1 more source